Fortress Biotech (NASDAQ:FBIO – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.79) per share and revenue of $16.30 million for the quarter.
Fortress Biotech Price Performance
Fortress Biotech stock opened at $1.72 on Tuesday. The business’s fifty day moving average is $1.72 and its 200 day moving average is $1.78. Fortress Biotech has a one year low of $1.36 and a one year high of $2.89. The stock has a market capitalization of $47.48 million, a PE ratio of -0.56 and a beta of 1.75.
Analyst Upgrades and Downgrades
Separately, Roth Mkm reaffirmed a “buy” rating and set a $16.00 price objective (up from $15.00) on shares of Fortress Biotech in a research report on Tuesday, March 11th.
Fortress Biotech Company Profile
Fortress Biotech, Inc, a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet.
Further Reading
- Five stocks we like better than Fortress Biotech
- What is the S&P 500 and How It is Distinct from Other Indexes
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- The 3 Best Fintech Stocks to Buy Now
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
